Lv4
414 积分 2026-04-12 加入
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
21小时前
已完结
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
21小时前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
21小时前
已完结
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study
11天前
已完结
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
11天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
11天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
11天前
已完结
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
11天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
11天前
已完结
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
11天前
已完结
皖公网安备34019202002308
